/PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) CEO and
President, Richard Garr, will
present at the World Stem Cells & Regenerative Medicine
Congress, on Thursday, May 22, at
11:35 a.m. BST in London, UK
(http://www.terrapinn.com/conference/stem-cells/index.stm).
Neuralstem is currently in a Phase II clinical trial to treat ALS
(Amyotrophic Lateral Sclerosis, or Lou
Gehrig's disease) with its NSI-566 stem cells and has been
approved to commence a Phase I study in spinal cord injury with the
same cells. The company has also completed a Phase Ib trial testing
its first-in-class neurogenic compound, NSI-189, in patients with
major depressive disorder (MDD).
GERMANTOWN, Md.,
May 16, 2014 Mr.
Garr's talk is called "Sustainable Growth of Regenerative Medicine:
Ensuring Long Term Development and Patient Access to Transformative
Cell Therapies." He will also give an update on the clinical
programs, including results from the NSI-189 Ib trial.
About Neuralstem
Neuralstem's patented technology enables the production of
neural stem cells of the brain and spinal cord in commercial
quantities, and the ability to control the differentiation of these
cells constitutively into mature, physiologically relevant human
neurons and glial cells. Neuralstem's NSI-566 spinal cord-derived
stem cell therapy is in Phase II clinical trials for amyotrophic
lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. Neuralstem has been
awarded orphan status designation by the FDA for its ALS cell
therapy.
In addition to ALS, the company is also targeting major
central nervous system conditions with its NSI-566 cell therapy
platform, including spinal cord injury and ischemic stroke. The
company has received FDA approval to commence a Phase I safety
trial in chronic spinal cord injury.
Neuralstem also maintains the ability to generate stable
human neural stem cell lines suitable for systematic screening of
large chemical libraries. Through this proprietary screening
technology, Neuralstem has discovered and patented compounds that
may stimulate the brain's capacity to generate neurons, possibly
reversing pathologies associated with certain central nervous
system conditions. The company has completed a Phase I safety trial
evaluating NSI-189, its first neurogenic small molecule product
candidate, for the treatment of major depressive disorder
(MDD). Additional indications might include traumatic brain
injury (TBI), Alzheimer's disease, and post-traumatic stress
disorder (PTSD).
For more information, please visit www.neuralstem.com or
connect with us on Twitter, Facebook and LinkedIn.
Cautionary Statement Regarding Forward Looking
Information:
This news release may contain forward-looking statements
made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Investors are cautioned
that such forward-looking statements in this press release
regarding potential applications of Neuralstem's technologies
constitute forward-looking statements that involve risks and
uncertainties, including, without limitation, risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem's
periodic reports, including the annual report on Form 10-K for the
year ended December 31, 2013 and Form
10-Q for the period ended March 31,
2014.
Logo
- http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO
SOURCE Neuralstem, Inc.